Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study-Reference-Cited by-同舟云学术

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study

Published:2021-05 Issue:10 Volume:9 Page:831-831
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann Transl Med

Author:

Yuan Yang,Zhang Shaohua,Yan Min,Yin Yongmei,Song Yuhua,Jiang Zefei

Publisher

AME Publishing Company

Subject

General Medicine

Link

https://atm.amegroups.com/article/download/70420/pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study;BMC Cancer;2024-07-30

2. Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast cancer;Journal of Molecular Cell Biology;2023-07-13

3. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer;Chinese Medical Journal;2023-04-27

4. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China;BMC Cancer;2023-01-30

5. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial;Oncology Research and Treatment;2023